Educational content on VJOncology is intended for healthcare professionals only. By visiting this website and accessing this information you confirm that you are a healthcare professional.

GU Cancers 2025 | Metastasis-directed radiotherapy in oligometastatic urothelial cancer

Comron Hassanzadeh • 6 Mar 2025

GU Cancers 2025

Bladder Cancer Genitourinary Cancer

Comron Hassanzadeh, MD, MPH, The University of Texas MD Anderson Cancer Center, Houston, TX, explores a single-institution retrospective study on the use of radiotherapy (RT)-based metastasis-directed therapy (MDT) in patients with oligometastatic bladder and upper tract cancer. Findings suggest that patients with a limited number of metastases may experience prolonged progression-free and overall survival. The findings ultimately highlight the potential role of MDT as an adjunct to systemic therapy. This interview took place at the ASCO GU Cancers Symposium 2025 in San Francisco, CA.

These works are owned by Magdalen Medical Publishing (MMP) and are protected by copyright laws and treaties around the world. All rights are reserved.